Kim A. Reiss Binder, MD

“Therapeutic targets are only found in a small percentage of all the patients. It’s not like half of them will have target X. But if you don't test, you're potentially denying the patient access to a drug or a trial for their specific tumor biology. That’s an important message to get out there.”

CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR) macrophage therapy by Carisma Therapeutics is being evaluated in a phase 1, first-in-human study (NCT04660929) for safety and tolerability in solid tumors with HER2 overexpression.

Data seen so far from the study were presented at the 

2022 American Society of Clinical Oncology (ASCO) meeting, held June 3-7, 2022, held both virtually and in Chicago, Illinois

 by Kim A. Reiss Binder, MD, assistant program director, Hematology/Oncology Fellowship Program, and assistant professor of medicine, University of Pennsylvania Hospital.

 spoke to Binder to learn more about the progress of the study and the potential of CAR macrophages in solid tumors. She stressed the importance of testing tumors for genetic markers for targeted therapies.

Reiss KA, Yuan Y, Ueno NT, et al. A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. Presented at: 2022 ASCO Meeting, June 3-7; Chicago, IL. Abstract # 2533

Videos

The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing. 

Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors 

This content originally appeared on our sister site, 

spoke with Kim A. Reiss Binder, MD, medical oncologist, assistant program director, Hematology/Oncology Fellowship Program, Abramson Cancer Center, Penn Medicine, assistant professor of medicine, Hospital of the University of Pennsylvania, about the initial results of a phase 1 trial (NCT04660929) evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

CT-0508 is being evaluated in an ongoing phase 1 trial in patients with HER2-overexpressing solid tumors. The cell therapy is comprised of autologous peripheral blood monocyte–derived macrophages that are transduced with an adenoviral vector containing a HER2-directed CAR and locked into an M1 phenotype.

Initial results of 2 patients treated with CT-0508 were presented during the 2021 SITC Annual Meeting. Regarding safety, 1 patient developed grade 2 cytokine release syndrome (CRS) characterized by fever and hypotension on day 3. The toxicity was resolved on day 4 with acetaminophen (Tylenol), cefepime (Maxipime), and fluids. The other patient, as well as 1 patient who was treated on study but not included in the poster presentation, did not develop CRS with CT-0508.

Although further data are needed to determine whether this therapy is safe, patients treated with CT-0508 are unlikely to develop severe CRS based on the therapy’s mechanism of action, Reiss Binder concludes.

The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.

Kim A. Reiss Binder, MD

Articles

Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors

Initial Results of CT-0508 in HER2+ Solid Tumors: Kim A. Reiss Binder, MD